Literature DB >> 18545008

Dry eyes: etiology and management.

Robert Latkany1.   

Abstract

PURPOSE OF REVIEW: Until recently, the cause of dry eye syndrome was uncertain and the treatment was palliative. Since discovering that dry eyes are caused by inflammation, there has been an abundance of research focusing on anti-inflammatory therapies, other contributing causes, and better diagnostic testing. This review summarizes some of the interesting published research on ocular surface disease over the past year. RECENT
FINDINGS: The definition of dry eye now highlights the omnipresent symptom of blurry vision. The re-evaluation of ocular surface staining, tear meniscus height, and visual change will allow for a better diagnosis and understanding of dry eyes. Punctal plugs, and oral and topical anti-inflammatory use will strengthen our arsenal against ocular surface disease.
SUMMARY: Major progress has occurred in the past few years in gaining a better understanding of the etiology of dry eye syndrome, which will inevitably lead to more effective therapeutic options.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18545008     DOI: 10.1097/ICU.0b013e3283023d4c

Source DB:  PubMed          Journal:  Curr Opin Ophthalmol        ISSN: 1040-8738            Impact factor:   3.761


  15 in total

Review 1.  The core mechanism of dry eye disease is inflammation.

Authors:  Yi Wei; Penny A Asbell
Journal:  Eye Contact Lens       Date:  2014-07       Impact factor: 2.018

Review 2.  Artificial tears potpourri: a literature review.

Authors:  Majid Moshirfar; Kasey Pierson; Kamalani Hanamaikai; Luis Santiago-Caban; Valliammai Muthappan; Samuel F Passi
Journal:  Clin Ophthalmol       Date:  2014-07-31

Review 3.  Pharmacological and therapeutic effects of A3 adenosine receptor agonists.

Authors:  Pnina Fishman; Sara Bar-Yehuda; Bruce T Liang; Kenneth A Jacobson
Journal:  Drug Discov Today       Date:  2011-10-19       Impact factor: 7.851

4.  Treatment of dry eye syndrome with orally administered CF101: data from a phase 2 clinical trial.

Authors:  Isaac Avni; Hanna J Garzozi; Irina S Barequet; Fanni Segev; David Varssano; Gil Sartani; Noa Chetrit; Erez Bakshi; David Zadok; Oren Tomkins; Gilad Litvin; Kenneth A Jacobson; Sari Fishman; Zivit Harpaz; Motti Farbstein; Sara Bar Yehuda; Michael H Silverman; William D Kerns; David R Bristol; Ilan Cohn; Pnina Fishman
Journal:  Ophthalmology       Date:  2010-03-20       Impact factor: 12.079

5.  Dry eye reversal and corneal sensation restoration with topical naltrexone in diabetes mellitus.

Authors:  Ian S Zagon; Matthew S Klocek; Joseph W Sassani; Patricia J McLaughlin
Journal:  Arch Ophthalmol       Date:  2009-11

6.  Osmoprotective effects of supplemental epidermal growth factor in an ex vivo multilayered human conjunctival model under hyperosmotic stress.

Authors:  Jae-hyung Kim; Soon-Suk Kang; Eun Soon Kim; Jae Yong Kim; Myoung Joon Kim; Hungwon Tchah
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2013-05-16       Impact factor: 3.117

7.  Dry eye syndrome.

Authors:  Mohammad-Ali Javadi; Sepehr Feizi
Journal:  J Ophthalmic Vis Res       Date:  2011-07

8.  Review of hydroxypropyl cellulose ophthalmic inserts for treatment of dry eye.

Authors:  Theresa Nguyen; Robert Latkany
Journal:  Clin Ophthalmol       Date:  2011-05-11

9.  Relationship between symptoms of dry eye syndrome and occupational characteristics: the Korean National Health and Nutrition Examination Survey 2010-2012.

Authors:  June-Hee Lee; Wanhyung Lee; Jin-Ha Yoon; Hongdeok Seok; Jaehoon Roh; Jong-Uk Won
Journal:  BMC Ophthalmol       Date:  2015-10-29       Impact factor: 2.209

Review 10.  Diagnostic procedures and management of dry eye.

Authors:  Snježana Kaštelan; Martina Tomić; Jasminka Salopek-Rabatić; Branko Novak
Journal:  Biomed Res Int       Date:  2013-08-19       Impact factor: 3.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.